Home     About Us     Team     Products     News     Contact     FAQ     Account

CD38 Monoclonal Antibodies

*Prices reflect U.S. average retail price

Darzalex (daratumumab)

In November 2015, the U.S. Food and Drug Administration approved daratumumab for treatment of multiple myeloma in patients who had received at least three prior therapies. In May 2016 daratumumab was also conditionally approved by the European Medicines Agency for treatment of multiple myeloma.

In November 2016, the FDA approved daratumumab in combination with lenalidomide or bortezomib and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy...Wikipedia

 

Manufacturer's Website: Darzalex

 

Average retail cost: $512/vial

Copyright 2006-2022 Automated Clinical Guidelines, LLC. All rights reserved.